National Resilience, Inc. (Resilience)

1.1 Identity, footprint, and delivery model

National Resilience, Inc. launched in 2020 as a biopharmaceutical manufacturing business and now describes itself as a North American contract development and manufacturing organization. Its current public positioning concentrates on biologics drug substance, sterile drug product, device assembly, and packaging rather than the broader modality portfolio in its launch-era materials. These are company descriptions, not independently audited measures of operating performance. The retained evidence does not establish a reconciled current site list, utilization, or facility-level capacity. Blue Ash, Ohio became the announced corporate headquarters in June 2026; that update should not be read as a disclosure of site-level output or workforce totals.[CO001, CO002, CO013]

1.2 Leadership and capital structure

The clearest leadership evidence identifies William S. Marth as president and chief executive officer in a Resilience-issued release carried by BioSpace, the October 2025 financing announcement, and independent reporting. Company materials describe his prior President/COO remit and earlier pharmaceutical leadership roles; the retained sources do not establish the current board roster, ownership rights, or succession depth. At launch, the company named Robert Nelsen as founder and chairman and Rahul Singhvi as founding CEO, but those launch-era titles do not establish present governance. Financing evidence must be separated by instrument and status: the company announced up to $825 million of long-term debt, including a $600 million first-lien commitment, with an initial $525 million tranche expected later in Q4 2025 subject to customary conditions. That is not equity raised or proof of cash currently available. Separate historical venture totals are publisher-attributed and cannot be combined with the debt commitment into a current cash balance. Private-company revenue, ARR, valuation, debt outstanding, and customer concentration remain unavailable in the assigned evidence.[CO003, CO004, CO005, CO007, CO008]

1.3 Portfolio reset and strategic milestones

The operating footprint has changed materially. BioPharma Dive reported in June 2025 that Resilience planned to wind down six sites after management said capacity expansion had outpaced industry demand; later reporting and company-issued material describe additional asset transfers and a more focused operating model. That history makes the reported footprint and financing plans execution signals, not evidence of utilization, profitability, or demand conversion. More recent public signals include the Blue Ash headquarters relocation and anticipated local hiring, plus a reported Lilly investment to expand Ohio injectable production, with full operations expected in 2027. The Lilly project is a meaningful commercial validation signal, but the evidence does not disclose contract economics, customer concentration, or how much of the announced investment has been deployed. The dated timeline below distinguishes completed events from plans and forecasts; it does not treat announced debt as funded cash or projected jobs as current employees.[CO010, CO011, CO012, CO013, CO014, CO015, CO016, CO017]

2.1 Define the market before sizing it

The broad CDMO category spans development and contract manufacturing across modalities; it is not a defensible proxy for Resilience's addressable market. Its current official materials emphasize biologics drug substance, while company materials and trade coverage also describe aseptic drug product, fill-finish, device assembly, and packaging. These are related but distinct service budgets and should not be collapsed into one spend pool. The company profile describes customers ranging from large pharmaceutical companies to small and mid-sized pharma and biotechnology firms, but that company-issued profile does not establish customer concentration or revenue by service. Cell-therapy manufacturing is an adjacent category in the reviewed evidence; recent footprint changes make its current relevance to the retained business uncertain. In-house capacity is a substitute for outsourced CDMO services, not part of external CDMO revenue. The market-definition table therefore separates the core service lines, adjacent modalities, and status quo rather than assigning every global CDMO dollar to Resilience.[CM009, CM010, CM012, CM013, CM014]

2.2 Reported estimates show scale, not a company-specific TAM

The available estimates do not form a single consistent series. Vision Life Sciences relays three broad CDMO estimates from Precedence Research, Grand View Research, and BCC Research, but explicitly warns that the firms define the market differently and that the figures are not directly comparable. Alira Health's 2025 report preview gives a separate biologics-CDMO estimate for 2024 and an advanced-therapies segment. Those figures offer an order-of- magnitude context, not a reconciled TAM/SAM calculation: the source methods and precise inclusion rules are not available in the reviewed text, and the estimates have different years and scopes. The chart preserves those source- attributed lenses in authored order, not as proportional or derived layers. A Resilience-specific SAM or SOM cannot be isolated without modality-level market definitions, site capacity and utilization, and company revenue or backlog by service. The numerical table keeps reported values and vintages distinct and records the uncertainty rather than averaging them.[CM001, CM002, CM003, CM004, CM005, CM006, CM007, CM008, CM016]

2.3 Buyer need is strongest where internal capacity is costly or slow

The customer set described in the evidence includes large pharma and smaller pharmaceutical and biotechnology sponsors. Their likely buying problem differs by program stage: early-stage sponsors need development and clinical manufacturing without building a full internal operation, while later-stage sponsors need qualified capacity, process continuity, and a path to commercial supply. Resilience says it accepts preclinical and early-phase programs and can carry work through commercial tech transfer; these are company claims, not independent proof of program wins or customer economics. A historical Contract Pharma interview with another CDMO's chief executive describes outsourcing as a way to reduce time to clinic and avoid staffing and capital commitments. That is useful as an industry mechanism, not a neutral benchmark. Specific internal budget owners, contract economics, switching costs, and the share of sponsor work awarded to Resilience are not disclosed in the retained evidence.[CM011, CM012, CM013, CM014]

2.4 Demand tailwinds coexist with capacity and policy risks

The market evidence points to biologics complexity and sponsor demand for outsourced expertise as structural demand drivers, but the Resilience coverage also documents the downside of building capacity ahead of demand: the company closed six underutilized facilities in 2025 after expansion outpaced industry demand. Its later focus on biologics and aseptic drug product is consistent with a narrower target market, but does not establish utilization or profitable growth. High facility cost and long build times can make outsourcing attractive, while qualification, technology transfer, quality systems, and schedule risk can slow adoption; the cited industry interview describes these commercial trade-offs rather than measuring them. Separately, Arnold & Porter explains that BIOSECURE Act implementation can constrain use of designated biotechnology suppliers in certain federal contracts and grant-funded procurement. This is a buyer-side compliance constraint and potential sourcing consideration, not evidence of a Resilience contract win or an automatic market-share benefit. A diligence case therefore needs evidence of program conversion, ramp timing, and customer-funded utilization alongside market growth.[CM009, CM010, CM011, CM015]

2.5 Exhibits

3.1 Competitive set and strategic position

The available evidence does not identify named direct CDMO peers or provide a peer-by-peer comparison of customer segments, revenues, utilization, or contract wins. It instead distinguishes broad public-market archetypes: larger scaled biologics manufacturers, smaller specialized platforms, and earlier-stage operators. Those categories are useful context, not a complete competitor enumeration. Resilience's own materials present a broad service offer from biologics drug substance through sterile fill/finish and downstream assembly, while reporting on its reset describes six site closures and a more concentrated operating footprint. The competitive thesis is therefore integration and investment in selected capabilities, not demonstrated superiority on price, share, or outcomes. Buyers can also compare an incumbent outsourced provider with a specialist provider or internal manufacturing, but the assigned sources do not establish which alternative wins a given program. A candidate CDMO directory page in the assigned evidence yielded only its publisher's registration line, so it did not resolve the missing named-peer roster.[CP001, CP003, CP004, CP008, CP009, CP011, CP014]

3.2 Capability, buyer fit, and commercial trade-offs

Company-published material describes a single quality system spanning early development through commercial supply, direct access to technical teams, and installed single-use capacity from 50 L to 2,000 L. Those are company claims, not independently audited throughput or customer outcomes. The evidence also describes Blue Ash packaging and device-assembly investment alongside a West Chester fill/finish expansion; the cited first-line commercial timing was an expectation in a July 2026 article, not a verified operating result. This combination may suit buyers seeking fewer transfers across development and supply stages, but no source quantifies transfer savings, switching costs, delivery reliability, or realized pricing. The matrix therefore separates documented Resilience claims from unverified peer and in-house comparisons.[CP001, CP002, CP004, CP011, CP012, CP013]

3.3 Public-market context is not a private-company benchmark

An Alira Health market update reports forward EV/EBITDA multiples of approximately 6x to above 30x across public CDMO platforms and describes larger scaled biologics manufacturers as trading at structural premiums relative to smaller or earlier-stage platforms. The range is broad and the source does not provide a Resilience-specific multiple, customer-level economics, or enough detail here to match a private business to a public comparator. It should frame diligence on the importance investors place on scale and execution, not be applied as a valuation input for Resilience. No retained source discloses comparable list prices, contract units, discounting, or realized rates, leaving procurement economics and switching behavior unresolved.[CP007, CP008, CP012, CP015]

3.4 Differentiation durability and downside evidence

The footprint reset is a material counterweight to a simple scale narrative: reporting describes six underutilized-site closures, and a September 2026 company release says the East Norriton cell-therapy facility was acquired by Made Scientific. At the same time, current expansion plans concentrate investment in Blue Ash, West Chester, and Toronto. The sources do not establish whether those assets are utilized, whether commercial lines meet launch schedules, or how much customer demand is contracted. This creates execution and concentration questions alongside the potential benefit of an integrated network. Before underwriting a durable moat, diligence should compare customer-level quality and on-time delivery, capacity utilization, renewal terms, and the cost and time required to transfer a program to another CDMO or to an internal facility.[CP003, CP004, CP005, CP013, CP016]

3.5 Exhibits

4.1 Service scope is visible; monetization is not

Resilience describes development and tech-transfer work from early-stage programs through commercial supply, plus biologics drug substance, sterile fill-finish, device assembly, and packaging. Its public capacity figures are equipment and site claims, not evidence of booked demand, annual throughput, recognized sales, or utilization. The operating model is therefore best understood as outsourced development and manufacturing services whose financial conversion depends on customer scope and contract terms that are not public. The revenue streams table separates company-described capabilities from reported financial performance. The flow is an illustrative service-to-economics path: customers may procure only selected stages, and no assigned source discloses billing units, realized price, or margin.[CI001, CI002, CI003, CI004, CI013]

4.2 Debt commitments and customer output are not revenue

Resilience announced up to $825 million of long-term debt financing from Oak Hill Advisors, including a $600 million first-lien commitment and an initial $525 million tranche then expected in the fourth quarter of 2025, subject to customary conditions. This announcement does not establish current cash, the amount actually drawn, debt outstanding, or runway. Resilience and Lilly separately described a $750 million investment in expanded Ohio manufacturing and reported more than 150 million doses produced over their multi-year partnership; neither figure is Resilience revenue or a disclosed share of customer economics. The September 2026 company announcement of an East Norriton divestiture, following earlier reported underutilized-site wind-downs, shows a continuing footprint reset, not proof that retained capacity is now fully absorbed.[CI005, CI006, CI007, CI008, CI009, CI017, CI011]

4.3 Private operating metrics still block unit-economics underwriting

No assigned public source reports current service-line revenue, realized prices, gross margin, customer concentration, site utilization, or operating cash flow. The historical report that capacity expansion outpaced demand makes fixed-cost absorption and ramp timing especially material; it is not a current utilization measure. Competitor-issued industry commentary argues that manufacturing economics include quality, delay, and supply-interruption costs as well as batch price, but it is qualitative context rather than an independent Resilience benchmark. The financial verdict is that the service portfolio and customer output are commercially relevant, while margin path, capital intensity, debt service, and cash conversion remain unproven. Before underwriting, obtain site- and customer-level financials, executed contract terms, backlog, working-capital needs, and the current debt and cash schedule.[CI017, CI012, CI013, CI014, CI015, CI016]

5.1 Product scope and maturity

Resilience sells manufacturing and development services rather than a single finished software product. Its official biotech FAQ describes support from preclinical and early phase through commercial tech transfer, while the drug-substance page presents biologics manufacturing as a program-specific service. The company says development uses single-use bioreactors from 3L to 500L and installed cGMP capacity ranges from 50L to 2,000L; those are company-reported capacity bands, not evidence of current utilization, validated throughput, or a customer's production outcome. The company's own pages also list process and analytical development, drug substance, and sterile fill/finish. Third-party directories describe broader cell, gene, RNA, and vaccine capabilities, but the assigned evidence does not independently establish current site-level readiness for each modality. The module matrix therefore separates documented service descriptions from listed-but-unverified platform breadth.[CE001, CE002, CE007, CE008]

5.2 Delivery workflow and operating footprint

The described customer workflow begins with process and analytical development, proceeds through stage-gated technology transfer and validation, and can continue into drug-substance and sterile drug-product manufacturing. Resilience says drug substance is manufactured in Toronto or supplied by the customer, while sterile fill/finish is offered at both Cincinnati and Toronto; it also says the clinical-to-commercial programs use one integrated quality system. These are descriptions of the offered model, not independently verified evidence that every program traverses every site or stage. External trade coverage records a footprint reset: Pharma Manufacturing reported plans to wind down six underutilized sites while retaining production in four named locations, and BioProcess International later reported a Blue Ash headquarters move and West Chester fill/finish-line investment. This makes site-specific transfer, qualification, and capacity evidence important to diligence.[CE003, CE004, CE005, CE010, CE011, CE012, CE015]

5.3 Architecture, quality controls, and operating risk

The evidence supports a capability-layer view, not a detailed equipment, data, or process architecture. Public company material gives development and installed-volume ranges, names a common quality-system approach, and describes a Type V facility Drug Master File and regulatory support; FDA material separately explains the general cGMP requirements that apply to drug manufacturing. Neither establishes Resilience's current inspection results, deviation history, release performance, cybersecurity controls, or site-by-site qualified capacity. The announced network consolidation and planned sterile-injectable expansion create execution dependencies around transfer, validation, staffing, and line qualification, but are not evidence of a failure. Investors should treat the absence of company-specific operating metrics in this source pool as an evidence gap rather than infer either poor performance or proven reliability. The assigned pool also contains no relevant practitioner- community, public-engineer, or integration-partner technical signal; this is a gap in the available evidence, not proof that no such signal exists.[CE002, CE005, CE006, CE012, CE013, CE014, CE015, CE016]

6.1 Buyers, users, and program segments

Resilience markets manufacturing and development services to biopharma and pharmaceutical sponsors, but the reviewed public materials do not identify the contracting buyer, payer, or account economics for individual programs. Its company pages describe biologics drug-substance work from the first clinical batch through commercial supply and list 50L to 2,000L manufacturing trains (CU001, CU003, CU004). A 2026 company release describes an integrated path through sterile fill/finish, device assembly, and packaging (CU005). CSIS notes that pharmaceutical manufacturers may rely on long-term CDMO relationships and qualified supplier redundancy; that is sector context, not evidence of Resilience's own contract mix (CU002). BIO's 2026 program lists a Resilience presentation with a regional sales and business-development speaker, evidence of event presence rather than customer wins (CU013). The table maps the documented segments and leaves account scale open.[CU001, CU002, CU003, CU004, CU005, CU013]

6.2 Adoption evidence is concentrated in Lilly

The clearest named production evidence is Lilly: Fierce Pharma reports that the companies teamed up in 2023, that Resilience's Ohio site has manufactured Mounjaro and Zepbound, and that Resilience had produced 150 million doses of Lilly medicines in vials and prefilled syringes (CU007, CU008). The same report describes a $750 million investment for Ohio upgrades focused on Lilly's KwikPen and at least 400 expected new jobs; full operations from the upgrade were expected to start in 2027 (CU009, CU010). Those are meaningful production and expansion signals, but they are not revenue, utilization, contract duration, or evidence that the planned capacity is already operating. Other named relationships in the 2025 reporting are described as a pact or alliances, without current-status or production-outcome detail (CU015, CU016). The trajectory table preserves each metric's stated unit and timing while flagging missing denominators.[CU007, CU008, CU009, CU010, CU015, CU016]

6.3 Portfolio reset raises customer-continuity questions

Resilience announced in September 2026 that Made Scientific acquired its East Norriton cell-therapy facility and said it is now focused on biologics and sterile drug-product manufacturing (CU011). Earlier, BioPharma Dive reported the planned wind-down of six underutilized sites after capacity expansion outpaced industry demand and said the company would focus resources on Cincinnati and Toronto (CU012). The sequence shows a material footprint reset alongside a later Lilly-linked expansion, not a uniformly growing customer base. In a separate 2025 financing announcement, Resilience described up to $825 million of debt financing, including an initial tranche then expected later that quarter. It said financing would support go-forward operations and customer service, but this is a historical commitment announcement, not evidence of current cash available or customer retention (CU006, CU014). No reviewed source quantifies renewals, churn, customer concentration, booked backlog, or account-level economics, leaving durability and delivery risk unresolved.[CU006, CU011, CU012, CU014]

6.4 Offered service path, not a measured conversion funnel

Resilience describes a route from first clinical batch through commercial supply, with drug substance, sterile fill/finish, device assembly, and packaging in its offering (CU004, CU005). The figure translates that company-described capability chain into an ordered workflow; it does not assert that every customer enters at the same point, progresses through every stage, or expands at a measurable rate. The public evidence names Lilly as a production relationship but does not provide customer-cohort conversion, renewal, or expansion data. The workflow is therefore a diligence map of described handoffs, while actual stage-by-stage adoption and the economics of each transition remain private-evidence questions.[CU003, CU004, CU005, CU007]

7.1 Footprint transition and operating concentration

The most visible operating risk is execution through repeated footprint changes, not a documented failure event. A trade publication reported that Resilience was winding down six underutilized locations while maintaining production at four named sites; in September 2026, the company said its East Norriton cell-therapy facility had been acquired by Made Scientific and described a narrower biologics and sterile drug-product focus. The retained pool also includes a report that OXB acquired Resilience's former Research Triangle site. This is evidence of portfolio change, not proof of customer disruption or underperformance. Resilience says drug substance runs at Toronto or is customer-supplied, while sterile fill/finish runs at both Cincinnati and Toronto; site-level capacity, utilization, transfer plans, and qualified backup routes remain unverified.[CR001, CR002, CR003, CR004, CR014]

7.2 Financing, partner dependence, and execution

Resilience announced up to $825 million of long-term debt financing from Oak Hill Advisors, with a $600 million first-lien commitment and an initial $525 million tranche expected in the fourth quarter of 2025, subject to customary conditions. The announcement is not evidence that all financing was funded or remains available; neither current net debt, cash, covenants, amortization, nor the amount drawn is established by the assigned sources. Separately, a Resilience-Lilly release described a $750 million joint investment, more than 150 million cumulative doses produced, and full operations for the KwikPen expansion expected in early 2027. These are meaningful execution and counterparty signals, but not revenue, contracted volume, customer share, or cash available. A delay or cost overrun would matter most if it coincides with debt service or weak utilization.[CR005, CR006, CR007, CR008, CR015, CR016]

7.3 Regulatory, quality, and legal exposure

The sources describe quality controls but do not verify their operating effectiveness. Resilience's own pages describe an integrated quality system and commercially licensed Cincinnati and Toronto sites; a current investigator job repost specifies deviation investigations, root-cause work, and corrective and preventive action (CAPA) effectiveness checks. Those statements establish described controls and a hiring requirement, not the volume or closure quality of actual deviations, inspection outcomes, recalls, or remediation. HHS-OIG guidance and federal false-claims law provide relevant compliance context for healthcare-sector entities. The assigned record of BIOSECURE legislation is historical and does not establish its status in October 2026 or Resilience's supplier exposure. No claim is made that an enforcement action or incident did or did not occur.[CR009, CR010, CR011, CR012, CR013]

7.4 Monitoring priorities and thesis-break tests

Diligence should tie the transition plan to operating evidence: obtain site-by-site utilization, qualified capacity, backlog and transfer status; current debt balances, draw conditions, covenants, and amortization; and customer-level revenue, contract duration, renewal, and volume commitments. For the Lilly expansion, compare the stated early-2027 start with validated qualification, hiring, and production milestones, while separating the historical dose count from future contracted demand. Obtain current inspection, audit, CAPA, recall, and litigation records directly from the company and relevant regulators. A missed ramp, material loss of a major program, unexpected debt restrictions, or a material quality finding would warrant reassessing the investment thesis; the sources do not quantify probabilities or establish thresholds for those events.[CR003, CR005, CR007, CR008, CR015, CR016]

7.5 Exhibits

8.1 Recommendation and entry discipline

The evidence supports a research-more recommendation, low confidence, high risk, and an unknown valuation stance—not a price target. Resilience describes technical capabilities and a sizeable Ohio footprint, while company-issued sources report Lilly production milestones (CV001, CV002, CV004, CV010). The financing announcement is for debt of up to $825 million, not an equity valuation or proof of cash on hand (CV006). A funding aggregator's cumulative figure combines financing categories and is not deployable cash (CV008). Without current revenue, EBITDA, cash conversion, net debt, utilization, or a fully diluted capitalization, a DCF, EV/revenue multiple, or investor return range would be false precision (CV016). Entry discipline is therefore to defer a price decision until management supplies these inputs and the financing documents; the summary below records what evidence would change the call.[CV001, CV002, CV004, CV006, CV008, CV010, CV016]

8.2 Investment thesis and anti-thesis

The positive case is operational rather than financial: company materials describe commercial-scale biologics and sterile-product capabilities, a multi-year Lilly relationship, and reported production above 150 million doses (CV004, CV009, CV010). These are evidence of capabilities and execution claims, not of backlog, customer concentration, margin, or cash yield. The anti-thesis is that the company has used long-term debt to fund a business reset, while reporting from Pharma Manufacturing describes an earlier bridge financing and six underutilized sites being wound down (CV006, CV007, CV012). A later company-issued update describes another non-core asset divestiture (CV013). The bull case needs audited economics and line-level utilization; the bear case strengthens if debt service, site absorption, or Lilly ramp timing weakens.[CV004, CV005, CV006, CV007, CV009, CV010, CV012, CV013]

8.3 Valuation frame and scenarios

The available references do not produce a defensible company multiple. The OHA financing is a debt commitment, not a transaction valuation; Clay's funding total aggregates disclosed financing and other sources rather than measuring current cash or equity value (CV006, CV007, CV008). OXB's disclosed $4.5 million purchase was for a specific viral-vector facility and asset package, not Resilience's retained enterprise, so it is not a comparable company valuation (CV014). Lilly's reported market capitalization describes a customer/partner, not Resilience or a CDMO peer multiple (CV005). Lonza's investor-relations page links to public reports and share information, while a historical Thermo Fisher revenue series offers only scale context; neither provides a Resilience-specific CDMO multiple (CV015). Scenario values and probabilities are intentionally not numeric: no revenue base, margins, debt balance, dilution, or exit multiple is evidenced. The framework below uses only directional signals; the flow figure shows why those signals stop at research-more.[CV006, CV007, CV008, CV014, CV015, CV016]

8.4 Diligence gates and thesis breaks

Before underwriting an entry, obtain audited statements and current management accounts, including revenue by site and customer, EBITDA and cash flow, working capital, capex, utilization, backlog, and contract duration. Reconcile the headline financing ceiling to funded amounts, current debt, maturity, pricing, collateral, covenants, and any preferred-equity or shareholder waterfall (CV007, CV008). Use SEC EDGAR search as a public-record check, not as evidence that no filing exists (CV003). Confirm the status and timing of the Lilly expansion against commissioning, qualification, and commercial-ramp milestones rather than treating planned jobs or early-2027 operations as realized (CV009, CV011). Thesis-break indicators are sustained utilization shortfalls, missed qualification or volume milestones, renewed facility exits, or debt terms that leave insufficient cash for the retained network. No target return, holding period, or exit value is supportable until those gaps close (CV012, CV013, CV016).[CV003, CV007, CV008, CV009, CV011, CV012, CV013, CV016]

8.5 Exhibits